RELAPSED NON-HODGKIN LYMPHOMA

This study is testing whether combining two existing drugs—pembrolizumab (an immunotherapy) and ATRA (a form of vitamin A)—can help control lymphoma that has come back or stopped responding to standard treatments. It is for adults with specific types of relapsed Hodgkin or B-cell…

This study is testing a two-step treatment for patients with large B-cell lymphoma that has come back or hasn't responded to other treatments. First, patients receive targeted radiation to all visible cancer sites to shrink large tumors. Then, they receive a personalized immune c…

This study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study is testing a personalized treatment called CAR T-cell therapy for people with aggressive lymphoma or acute lymphoblastic leukemia that has returned or not responded to standard treatments. Doctors collect a patient's own immune cells, genetically modify them in a lab t…

This study is testing a new combination treatment for aggressive non-Hodgkin lymphoma that has returned or not responded to standard therapies. It will give 22 patients a three-part regimen: first a personalized cell therapy (CAR-T), followed by two other drugs. The main goal is …

This study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 …

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…